Who is sponsoring NCT06223100?

NCT06223100 is sponsored by Sichuan Provincial People's Hospital.

What condition does NCT06223100 study?

NCT06223100 studies Immune Dysregulation Disorder.

What is the status of NCT06223100?

NCT06223100 is currently UNKNOWN.

Last reviewed 2024-01-25 · How we verify

Efficacy and Safety of the Combination Therapy Based on Eravacycline in Immunocompromised Hosts With MDROS Infection

NCT06223100 UNKNOWN

The goal of this observational study is to explore the treatment mode and clinical outcome of patients with immunocompromised who received the combined regimen of eraracycline in the treatment of multidrug-resistant bacterial infections, to evaluate the efficacy and safety of the combined regimen of eravacycline in the treatment of multidrug-resistant bacterial infections in immunocompromised host populations, and to provide data reference for the treatment of immunocompromised populations.

Details

Lead sponsor	Sichuan Provincial People's Hospital
Status	UNKNOWN
Enrolment	100
Start date	Thu Feb 01 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Wed Dec 31 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Immune Dysregulation Disorder

Interventions

Eravacycline